2nd Transatlantic Exchange Program focusses on Artificial Intelligence and Data Science in Oncology
Hundreds of attendees (on-site and virtually) joined the 2nd Transatlantic Exchange program on Friday, 5 May 2023, in Paris, France. The day-long session focused on artificial intelligence (AI) and data science in oncology.
The Masterclass presented in collaboration with Dana-Farber Cancer Institute...
Learn more >
Next-Generation Drug Improves Progression-Free Survival in Relapsed Chronic Lymphocytic Leukemia
A head-to-head clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has found that zanubrutinib, a next-generation BTK inhibitor, was more effective at preventing disease progression and better tolerated than ibrutinib, the...
Learn more >
Dana-Farber research supports FDA approval of new therapy for certain patients with ovarian cancer
A novel antibody drug conjugate therapy whose clinical trial testing has been co-led by Ursula Matulonis, MD, of the Dana-Farber Cancer Institute has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) on November 14 for the treatment of recurrent platinum-resistant...
Learn more >
Symposium highlights 75 years of Dana-Farber science
Seventy-five years of research that has recast the understanding, treatment, and prevention of cancer took center stage at the Dana-Farber 2022 Scientific Symposium on Sept. 29.
The all-day event featured nearly 20 presentations on topics such as the evolution of basic research at the Institute, the...
Learn more >
Three-drug combination slows progression of advanced kidney cancer
Patients treated with the three-drug combination had a 27% lower risk of progression or death compared to those on the two immunotherapy drugs.
COSMIC-313 trial is the first phase 3 trial in metastatic renal cell carcinoma to use nivolumab plus ipilimumab, a contemporary standard of care, as the...
Learn more >
Dana-Farber Cancer Institute Celebrates 75th Anniversary
Commemoration to showcase decades of progress and leadership in cancer care and research
Dana-Farber Cancer Institute is launching a year-long celebration of its 75th anniversary to highlight its history and progress in cancer care and transformative cancer research. In marking the notable...
Learn more >